ITL Health Group is an innovative global medical technology company, supplier and strategic partner that provides products and solutions to healthcare markets and empowers individual health management. ITL Health Group maintains two divisions including ITL BioMedical and MyHealthTest and is listed on the Australian Stock Exchange (ASX: ITD). Our IP portfolio of more than 50 patents sets standards for essential products through innovation and by leveraging market intelligence to optimise end-user safety and efficiency and meet stringent clinical demands and regulatory requirements. Our global footprint serves blood banks, hospitals and health systems, laboratories and veterinary and animal production facilities in more than 55 countries throughout N. America, S. America, Europe, Asia, Middle East and Australia. We are a growing provider of specialty ancillary products for the blood culture testing market estimated to be worth US$3.3b in 2016 growing to US$4.8b by 2021, via MarketsandMarkets. ITL BioMedical sets industry standards for the innovative design and production of biological sampling systems for human and animal use and medical, and surgical products for hospitals and clinics. Our ergonomic and patented products focus on safety, efficiency and productivity for end-users and patients to support clinical best outcomes in healthcare markets worldwide. Brands of ITL BioMedical include ITL Clinical and SampLok. MyHealthTest, a wholly owned subsidiary of ITL Health Group, offers a new generation in pathology testing. The MyHealthTest website allows consumers to conveniently order tests and take samples in the privacy of their own home. Samples are then processed by a fully accredited laboratory ensuring the accuracy and reliability of results. As of January 2018 MyHealthTest is marketing four tests, the HbA1c diabetes test and the Thyroid TSH test, and will launch its Cholesterol and Prostate tests imminently. Learn more https://www.itlhealthgroup.com